AIMS: Animal studies show that transforming growth factor-β1 (TGF-β1) is an important mediator of atrial fibrosis and atrial fibrillation (AF). This study investigated the role of TGF-β1 in human AF and the mechanism of atrial-selective fibrosis. METHODS AND RESULTS: Atrial specimens from 17 open heart surgery patients and left atrial and ventricular specimens from 17 explanted hearts were collected to assess the relationship between TGF-β1, AF, and differential atrial vs. ventricular TGF-β1 levels. A transgenic mouse model overexpressing active TGF-β1 was used to study the mechanisms underlying the resultant atrial-selective fibrosis. Higher right atrial total TGF-β1 levels (2.58 ± 0.16-fold, P < 0.0001) and active TGF-β1 (3.7 ± 0.7-fold, P = 0.013) were observed in those that developed post-operative AF. Although no ventricular differences were observed, 11 explanted heart failure hearts exhibited higher atrial TGF-β1 levels than 6 non-failing hearts (2.30 ± 0.87 fold higher, P < 0.001). In the transgenic mouse, TGF-β1 receptor-1 kinase blockade resulted in decreased atrial expression of fibrosis-related genes. By RNA microarray analyses in that model, 80 genes in the atria and only 2 genes in the ventricle were differentially expressed. Although these mice atria, but not the ventricles, exhibited increased expression of fibrosis-related genes and phosphorylation of Smad2, there were no differences in TGF-β1 receptor levels or Smads in the atria compared with the ventricles. CONCLUSIONS: TGF-β1 mediates selective atrial fibrosis in AF that occurs via TGF-β Receptor 1/2 and the classical Smad pathway. The differential atrial vs. ventricular fibrotic response occurs at the level of TGF-β1 receptor binding or phosphorylation.
AIMS: Animal studies show that transforming growth factor-β1 (TGF-β1) is an important mediator of atrial fibrosis and atrial fibrillation (AF). This study investigated the role of TGF-β1 in humanAF and the mechanism of atrial-selective fibrosis. METHODS AND RESULTS: Atrial specimens from 17 open heart surgery patients and left atrial and ventricular specimens from 17 explanted hearts were collected to assess the relationship between TGF-β1, AF, and differential atrial vs. ventricular TGF-β1 levels. A transgenic mouse model overexpressing active TGF-β1 was used to study the mechanisms underlying the resultant atrial-selective fibrosis. Higher right atrial total TGF-β1 levels (2.58 ± 0.16-fold, P < 0.0001) and active TGF-β1 (3.7 ± 0.7-fold, P = 0.013) were observed in those that developed post-operative AF. Although no ventricular differences were observed, 11 explanted heart failure hearts exhibited higher atrial TGF-β1 levels than 6 non-failing hearts (2.30 ± 0.87 fold higher, P < 0.001). In the transgenic mouse, TGF-β1 receptor-1 kinase blockade resulted in decreased atrial expression of fibrosis-related genes. By RNA microarray analyses in that model, 80 genes in the atria and only 2 genes in the ventricle were differentially expressed. Although these mice atria, but not the ventricles, exhibited increased expression of fibrosis-related genes and phosphorylation of Smad2, there were no differences in TGF-β1 receptor levels or Smads in the atria compared with the ventricles. CONCLUSIONS: TGF-β1 mediates selective atrial fibrosis in AF that occurs via TGF-β Receptor 1/2 and the classical Smad pathway. The differential atrial vs. ventricular fibrotic response occurs at the level of TGF-β1 receptor binding or phosphorylation.
Authors: Emelia J Benjamin; Peng-Sheng Chen; Diane E Bild; Alice M Mascette; Christine M Albert; Alvaro Alonso; Hugh Calkins; Stuart J Connolly; Anne B Curtis; Dawood Darbar; Patrick T Ellinor; Alan S Go; Nora F Goldschlager; Susan R Heckbert; José Jalife; Charles R Kerr; Daniel Levy; Donald M Lloyd-Jones; Barry M Massie; Stanley Nattel; Jeffrey E Olgin; Douglas L Packer; Sunny S Po; Teresa S M Tsang; David R Van Wagoner; Albert L Waldo; D George Wyse Journal: Circulation Date: 2009-02-03 Impact factor: 29.690
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin Journal: Circulation Date: 2003-05-27 Impact factor: 29.690
Authors: Gregory M Marcus; Mary A Whooley; David V Glidden; Ludmila Pawlikowska; Jonathan G Zaroff; Jeffrey E Olgin Journal: Am Heart J Date: 2007-10-25 Impact factor: 4.749
Authors: Padmini Sirish; Ning Li; Valeriy Timofeyev; Xiao-Dong Zhang; Lianguo Wang; Jun Yang; Kin Sing Stephen Lee; Ahmed Bettaieb; Sin Mei Ma; Jeong Han Lee; Demetria Su; Victor C Lau; Richard E Myers; Deborah K Lieu; Javier E López; J Nilas Young; Ebenezer N Yamoah; Fawaz Haj; Crystal M Ripplinger; Bruce D Hammock; Nipavan Chiamvimonvat Journal: Circ Arrhythm Electrophysiol Date: 2016-05
Authors: Mohit K Turagam; Mahek Mirza; Paul H Werner; Jasbir Sra; David C Kress; A Jamil Tajik; Arshad Jahangir Journal: Cardiol Rev Date: 2016 Mar-Apr Impact factor: 2.644
Authors: N Schlabritz-Loutsevitch; K Apostolakis-Kyrus; R Krutilina; G Hubbard; M Kocak; Z Janjetovic; S Sathanandam; A T Slominski; G Mari; E Dick Journal: J Med Primatol Date: 2016-09-15 Impact factor: 0.667
Authors: Irina A Polejaeva; Ravi Ranjan; Christopher J Davies; Misha Regouski; Justin Hall; Aaron L Olsen; Qinggang Meng; Heloisa M Rutigliano; Derek J Dosdall; Nathan A Angel; Frank B Sachse; Thomas Seidel; Aaron J Thomas; Rusty Stott; Kip E Panter; Pamela M Lee; Arnaud J Van Wettere; John R Stevens; Zhongde Wang; Rob S MacLeod; Nassir F Marrouche; Kenneth L White Journal: J Cardiovasc Electrophysiol Date: 2016-08-30